IVBXF — Innovent Biologics Inc/ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 1774163 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-08-25
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 41,616,652,000 | 17,380,396,000 | 20,870,812,000 |
| Dec 2025 | — | — | — | — | 37,347,839,000 | 17,344,705,000 | 17,991,596,000 |
| Jun 2025 | — | — | — | — | 23,594,272,000 | 9,540,139,000 | 9,172,452,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-13,839,661,000
Inventory
$1,876,786,000
Receivables
—
ST Investments
$2,622,589,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,706,229,760
EBITDA
$1,702,771,968
Free Cash Flow
$3,228,137,984
Enterprise Value
$2,618,083,584
Total Cash
$20,002,985,984
Total Debt
$2,323,205,888
Shares Out
1,743,864,650
Trailing EPS
$0.07
Book Value
$1.79
ROE
7.0%
ROA
2.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,041,523,000 | 2,140,913,000 | 813,565,000 | 37,347,839,000 | 17,991,596,000 | 19,356,243,000 | 10,001,012,000 |
| Dec 2024 | 9,421,888,000 | 258,119,000 | -94,631,000 | 21,602,602,000 | 8,484,873,000 | 13,117,729,000 | 1,287,024,000 |
| Dec 2023 | 6,206,070,000 | -909,210,000 | -1,027,913,000 | 20,627,360,000 | 8,099,779,000 | 12,527,581,000 | 147,810,000 |
| Dec 2022 | 4,556,380,000 | -2,581,885,000 | -2,179,270,000 | 17,588,845,000 | 6,858,896,000 | 10,729,949,000 | -1,918,804,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC. | $254.47B | $686.79 | — |
| IBM | INTERNATIONAL BUSINESS MACHINES CORP | $218.41B | $231.09 | — |
| KLAC | KLA CORP | $188.36B | $144.56 | — |
| DHR | DANAHER CORP /DE/ | $158.71B | $225.77 | — |
| LMT | LOCKHEED MARTIN CORP | $136.37B | $590.34 | — |
News headlines (Yahoo Finance, 1h cache)
Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
2026-11-17 21:37 · Yahoo
Innovent Announces Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-squamous Non-Small Cell Lung Cancer
2026-11-16 00:00 · Yahoo
Innovent Biologics (SEHK:1801) Extends Its Drug Data Momentum, Is It A Bargain?
2026-11-14 08:15 · Yahoo
Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List
2026-11-14 03:48 · Yahoo
Innovent Biologics (SEHK:1801) Stock Still Looks Undervalued As 3 Year Gain Nears 90%
2026-11-13 20:13 · Yahoo
What Does Innovent Biologics (SEHK:1801) IAR177 Data Say About Its Autoimmune Push?
2026-11-13 13:13 · Yahoo
Eli Lilly Stocks Rise as China Approves Orforglipron Weight-Loss Pill
2026-11-13 11:57 · Yahoo
Innovent Showcases Preclinical Data of its First-in-Class IL-6 x TL1A Bispecific Antibody at ACR Convergence 2026
2026-11-13 00:00 · Yahoo
Eli Lilly beats Novo to oral China GLP-1RA market on NMPA approval
2026-11-12 16:42 · Yahoo
Eli Lilly secures first approval for weight-loss pill in China
2026-11-12 16:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.